As preclinical studies indicate a role of Src in pancreatic cancer and that a biomarker may predict response to the Src inhibitor saracatinib, the Phase II Consortium (P2C) conducted a phase II clinical and biological study of saracatinib, an oral Src inhibitor, in gemcitabine-resistant metastatic pancreas cancer patients. This evidence concerns the gene SRC and familial pancreatic carcinoma.